Excelsior Biopharma Inc. (TPEX:6496)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.30
-0.20 (-0.75%)
At close: Feb 11, 2026

Excelsior Biopharma Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
898.26861.91771.56671.761,338
Revenue Growth (YoY)
4.22%11.71%14.86%-49.81%-7.29%
Cost of Revenue
538.1479.82464.63384.591,045
Gross Profit
360.17382.1306.93287.17293.35
Selling, General & Admin
438.24377.21324.57277.82241.65
Research & Development
96.0983.6262.5142.3256
Other Operating Expenses
-2.56----
Operating Expenses
531.77463.07388.06316.47302.12
Operating Income
-171.6-80.97-81.13-29.29-8.77
Interest Expense
-7.77-8.02-6.37-4.35-4.54
Interest & Investment Income
1.263.425.244.170.41
Earnings From Equity Investments
2.180.25---
Currency Exchange Gain (Loss)
--4.94-1.55-1.281.81
Other Non Operating Income (Expenses)
3.582.871.863.680.9
EBT Excluding Unusual Items
-172.34-87.39-81.95-27.06-10.19
Other Unusual Items
-0-1.070.16
Pretax Income
-172.34-87.39-81.95-25.99-10.03
Income Tax Expense
10.8311.329.067.765.62
Net Income
-183.17-98.71-91.01-33.76-15.65
Net Income to Common
-183.17-98.71-91.01-33.76-15.65
Shares Outstanding (Basic)
4646464647
Shares Outstanding (Diluted)
4646464647
Shares Change (YoY)
0.07%0.42%0.15%-1.42%-5.56%
EPS (Basic)
-3.97-2.14-1.98-0.74-0.34
EPS (Diluted)
-3.97-2.14-1.98-0.74-0.34
Free Cash Flow
-175.67-356.95-170.41-2.352.95
Free Cash Flow Per Share
-3.81-7.74-3.71-0.051.14
Gross Margin
40.10%44.33%39.78%42.75%21.92%
Operating Margin
-19.10%-9.40%-10.51%-4.36%-0.66%
Profit Margin
-20.39%-11.45%-11.80%-5.03%-1.17%
Free Cash Flow Margin
-19.56%-41.41%-22.09%-0.34%3.96%
EBITDA
-99.92-65.64-69.31-16.416.39
EBITDA Margin
-11.12%-7.62%-8.98%-2.44%0.48%
D&A For EBITDA
71.6815.3311.8212.8815.15
EBIT
-171.6-80.97-81.13-29.29-8.77
EBIT Margin
-19.10%-9.40%-10.51%-4.36%-0.66%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.